Monitoring of Residual Disease in Adult Acute Lymphoblastic Leukemia: Towards Personalized Medicine

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 302

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

CIGS15_445

تاریخ نمایه سازی: 13 بهمن 1398

چکیده مقاله:

Background: Ig/TCR receptor rearrangements QPCR technology is considered as a powerful method for minimal residual disease (MRD) detection in Acute Lymphoblastic Leukemia (ALL). In the present study, we evaluated an ASO (Allele Specific Oligonucleotide)-qPCR assay for MRD detection in adult ALL patients.Methods: Ninety-eight newly diagnosed ALL patients were enrolled in this study. V/J-usage was first identified in each diagnostic sample. Specific primers were designed based on unique sequence of hyper-variable regions in each patient. 2.5-year monthly MRD quantification was performed using ASO-qPCR method, for detection and screening of patient-specific Ig/TCR receptor rearrangements. Results: From 98 ALL patients, 72 were enrolled in our study for MRD screening. Clonal Ig/TCR gene rearrangements were detected in each patient. MRD detection was performed with one-month interval time in each case. Regarding the MRD threshold, patients were classified into two distinct groups of low-risk and high-risk. It was found that 2.5-year overall survival was significantly lower in high-risk group. Multivariate analysis showed that MRD-level at day 28 of induction therapy and onwards are the only significant prognostic factor. Clinical relapse was predictable in relapsed cases. Discussion: ASO-qPCR is a sensitive method for MRD detection. Patient classification and identification of those with a high-risk of relapse would be possible with MRD monitoring. MRD-levels at the end of induction therapy up to day 88 of therapy showed a strong association with patients’ outcome. MRD-based risk assessment is a precise approach which leads to personalized medicine in adult ALL through accurate risk group assignment with risk-adapted therapy.

کلیدواژه ها:

نویسندگان

Sepideh Shahkarami

Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Roya Mehrasa

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Samareh younesian

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Javad Tavakkoly-Bazzaz

Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Seyed H. Ghaffari

Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Ardeshir Ghavamzadeh

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.